Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173531 · ClinicalTrials.gov registry record · Phase 3
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
A Phase 3 study of Hyperphagia in Prader-Willi Syndrome, sponsored by ACADIA Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT06173531 is a Phase 3 study of Hyperphagia in Prader-Willi Syndrome that is active but no longer recruiting, run by ACADIA Pharmaceuticals. The registered enrollment target is 170 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT06173531, a Phase 3 study of Hyperphagia in Prader-Willi Syndrome, is active but no longer recruiting, sponsored by ACADIA Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Carbetocin
Study Locations (20)
California
- University of California Irvine - Orange
- Stanford University School of Medicine - Palo Alto
- Rady Children's Hospital San Diego - San Diego
Missouri
- Children's Mercy Hospital - Kansas City
- SSM Health/Saint Louis University - St Louis
Texas
- Cook Children's Health Care System - Fort Worth
- Christus Children's - San Antonio
Alabama
- Children's of Alabama - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2025-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06173531
The ClinicalTrials.gov registry entry for NCT06173531 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperphagia in Prader-Willi Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06173531 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT06173531 about?
NCT06173531 is a clinical study titled "Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome". 12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
What is the current status of trial NCT06173531?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2023-11-27. Estimated completion is 2025-11.
What conditions does trial NCT06173531 study?
This clinical trial studies the following conditions: Hyperphagia in Prader-Willi Syndrome.
What interventions are being tested in trial NCT06173531?
The interventions under investigation include: Placebo (DRUG), Carbetocin (DRUG).
Who is sponsoring clinical trial NCT06173531?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173531 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.